Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19082283 | METHODS FOR TREATING CANCER, REDUCING SIDE EFFECTS OF CANCER TREATMENT, AND PREVENTING THE RECURRENCE OF CANCER | March 2025 | November 2025 | Allow | 8 | 1 | 1 | Yes | No |
| 19072656 | KRAS INHIBITORS | March 2025 | December 2025 | Allow | 9 | 2 | 1 | Yes | No |
| 19069464 | Cannabichromene Derivatives And Use Thereof | March 2025 | July 2025 | Allow | 4 | 1 | 0 | No | No |
| 18920528 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | October 2024 | February 2026 | Allow | 16 | 2 | 0 | Yes | No |
| 18684845 | HETEROCYCLIC COMPOUND ACTING ON G12D MUTANT KRAS PROTEIN | February 2024 | January 2026 | Allow | 23 | 2 | 0 | Yes | Yes |
| 18267330 | N-BENZYL-ALPHA-AMINOAMIDES AS ANAPHASE-PROMOTING COMPLEX/CYCLOSOME (APC/C) INHIBITORS | June 2023 | February 2026 | Allow | 32 | 1 | 0 | Yes | No |
| 18137294 | [6R]-MTHF IN B6 ENHANCED 5-FU BASED CHEMOTHERAPY OF PANCREATIC CANCER | April 2023 | July 2025 | Abandon | 27 | 1 | 0 | No | No |
| 18246247 | 1H-PYRROLO[2,3-C]PYRIDINE COMPOUNDS AND APPLICATION THEREOF | March 2023 | October 2025 | Allow | 31 | 0 | 0 | Yes | No |
| 18004504 | BENZODIAZEPINE DERIVATIVES USEFUL IN TREATING A RESPIRATORY SYNCYTIAL VIRUS INFECTION | January 2023 | November 2025 | Allow | 35 | 0 | 1 | No | No |
| 18009182 | 2-AMINOQUINAZOLINONE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS | December 2022 | January 2026 | Allow | 38 | 0 | 1 | Yes | No |
| 17916535 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING AND PREVENTING ACUTE RESPIRATORY DISTRESS SYNDROME ASSOCIATED WITH VIRAL INFECTIONS | September 2022 | March 2026 | Allow | 41 | 1 | 0 | Yes | No |
| 17950314 | COMBINATION OF A BTK INHIBITOR AND AN INHIBITOR OF CDK9 TO TREAT CANCER | September 2022 | November 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17911235 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING AZOLE DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | September 2022 | October 2025 | Abandon | 37 | 0 | 1 | No | No |
| 17910536 | BENZO FIVE-MEMBERED CYCLIC COMPOUND | September 2022 | February 2026 | Abandon | 41 | 1 | 0 | No | No |
| 17904412 | MACROCYCLIC INDOLE DERIVATIVES AS INHIBITORS OF MCL-1 | August 2022 | January 2026 | Abandon | 41 | 0 | 1 | No | No |
| 17756275 | G9a INHIBITOR | July 2022 | February 2026 | Allow | 45 | 1 | 1 | Yes | No |
| 17758733 | ARYL OR HETEROARYL PYRIDONE OR PYRIMIDINE DERIVATIVE, PREPARATION METHOD AND USE THEREOF | July 2022 | September 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17831145 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | June 2022 | November 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17735564 | Interleukin 10 Conjugates and Uses Thereof | May 2022 | December 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17769177 | SYNTHESIS OF TYROSINE KINASE INHIBITORS | April 2022 | December 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17754131 | HETEROCYCLIC DERIVATIVE AND USE THEREOF | March 2022 | November 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17761944 | SALTS OF OMECAMTIV MECARBIL AND SOLID FORMS THEREOF | March 2022 | March 2026 | Abandon | 48 | 2 | 0 | No | No |
| 17635938 | OXO SIX-MEMBERED CYCLOPYRIMIDINE COMPOUND, PREPARATION METHOD AND MEDICAL USE THEREOF | February 2022 | September 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17630569 | SYNTHESIS OF mRNA DELIVERY AGENT | January 2022 | September 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17630650 | INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR | January 2022 | May 2025 | Allow | 40 | 0 | 1 | Yes | No |
| 17505533 | COMPOSITIONS OF MECHANICALLY INTERLOCKED, TOPOLOGICALLY COMPLEX CROSSLINKERS AND POLYMERS AND METHODS OF MAKING AND USING SAME | October 2021 | August 2025 | Allow | 46 | 1 | 1 | No | No |
| 17603107 | METHOD FOR PREPARATION OF CARSALAM | October 2021 | April 2025 | Allow | 42 | 0 | 1 | Yes | No |
| 17487106 | CRYSTAL FORM A OF 2-(2, 5-DIOXOPYRROLIDIN-1YL) ETHYL METHYL FUMARATE, PREPARATION METHOD THEREFOR AND USE THEREOF | September 2021 | December 2025 | Abandon | 51 | 2 | 1 | No | No |
| 17293375 | VANADIUM COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | May 2021 | November 2025 | Allow | 54 | 1 | 1 | No | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner VISHNYAKOVA, ELENA VLADIMIROVNA works in Art Unit 1691 and has examined 4 patent applications in our dataset. With an allowance rate of 75.0%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 51 months.
Examiner VISHNYAKOVA, ELENA VLADIMIROVNA's allowance rate of 75.0% places them in the 40% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by VISHNYAKOVA, ELENA VLADIMIROVNA receive 1.00 office actions before reaching final disposition. This places the examiner in the 8% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by VISHNYAKOVA, ELENA VLADIMIROVNA is 51 months. This places the examiner in the 4% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +33.3% benefit to allowance rate for applications examined by VISHNYAKOVA, ELENA VLADIMIROVNA. This interview benefit is in the 81% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 3% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 4% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.